Ginkgo Bioworks Holdings, Inc. (DNA) › Cash & EquivalentsGinkgo Bioworks Holdings, Inc. (DNA) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2019: $495.29M2020: $380.80M2021: $1.55B2022: $1.32B2023: $944.07M2024: $561.57M2025: $167.20M$167.20M2019Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$167.20M-70.2%2024$561.57M-40.5%2023$944.07M-28.3%2022$1.32B-15.1%2021$1.55B+307.0%2020$380.80M-23.1%2019$495.29M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share